TFFP
TFF Pharmaceuticals, Inc.
Set alert
52-week range unavailable
- Open
- 0.0902
- Prev close
- 0.065
- Mkt cap
- 288.80K
- Vol
- 11.02M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0611
- High
- 0.0902
- Forward P/E
- -0.02
- Beta
- 1.32
- Short ratio
- 1.77
- Inst. own
- 24.37%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.15
- 200-d avg
- 2.39
- 1y target
- 0.00
Key statistics
- Market cap
- 288.80K
- Enterprise value
- -3.05M
- Trailing P/E
- 0.00
- Forward P/E
- -0.02
- PEG ratio
- 0.00
- Price / sales
- 0.24
- Price / book
- 0.02
- EPS (TTM)
- -5.50
- Beta
- 1.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.20M
- Revenue growth
- 95.10%
- Free cash flow
- -6.48M
- Total cash
- 4.39M
- Total debt
- 74.12K
- Return on equity
- -213.51%
- Shares outstanding
- 4.44M
- Short % of float
- 5.02%
- 50-day average
- 1.15
- 200-day average
- 2.39
Analyst view
Consensus: none
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 20, 2024 | Sep 1, 2024 | 0.00 | -0.81 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -1.70 | -1.22 | +0.48 | +28.24% |
| May 14, 2024 | Mar 1, 2024 | -2.20 | -2.40 | -0.20 | -9.09% |
| Mar 28, 2024 | Dec 1, 2023 | -2.00 | -2.01 | -0.01 | -0.50% |
| Nov 14, 2023 | Sep 1, 2023 | -2.75 | -2.25 | +0.50 | +18.18% |
| Aug 15, 2023 | Jun 1, 2023 | -5.00 | -3.50 | +1.50 | +30.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 28, 2024 | Roth MKM | main | Buy | Buy |
About TFF Pharmaceuticals, Inc.
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tffpharma.com
News
- TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
- Why Domino's Pizza Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
- TFF Pharmaceuticals Announces It Will Wind Down Operations
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- TFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's Why
Your note
Sign in to keep a note on TFFP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARLSON CAPITAL, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 15, 2023 | 0 |
| COLEMAN KIRK ALLEN | Chief Financial Officer | Stock Award(Grant) | Jul 2, 2024 | 45,859 |
| KING THOMAS BRAXTON | Director | Stock Award(Grant) | Jul 2, 2024 | 1,583 |
| LEE CATHERINE CHAI-ZON | Director | Stock Award(Grant) | Jul 2, 2024 | 1,583 |
| MIKHAK ZAMANEH | Officer | Stock Award(Grant) | Jul 2, 2024 | 145,184 |
| MILLS ROBERT S | Director | Stock Award(Grant) | Jul 2, 2024 | 59,145 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Carlson Capital. L.P. | 6.60% | 293,460 | 19.07K | Sep 29, 2024 |
| Armistice Capital, LLC | 5.13% | 228,000 | 14.82K | Sep 29, 2024 |
| Westside Investment Management, Inc. | 1.69% | 75,264 | 4.89K | Sep 29, 2024 |
| Drw Securities, Llc | 0.90% | 40,000 | 2.60K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.63% | 27,999 | 1.82K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.46% | 20,497 | 1.33K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.46% | 20,618 | 1.34K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.26% | 11,762 | 764 | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 5,326 | 346 | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 4,951 | 321 | Oct 30, 2024 |